LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 2771

Search options

  1. Article: DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors.

    Yin, Dong / Xie, Dong / Hofmann, Wolf-Karsten / Zhang, Wenxuan / Asotra, Kamlesh / Wong, Rex / Black, Keith L / Koeffler, H Phillip

    Molecular carcinogenesis

    2003  Volume 36, Issue 1, Page(s) 23–31

    Abstract: ... groups from the O(6) position of guanine. We found a significantly increased frequency of G:C to A:T ... an unmethylated MGMT promoter (P < 0.05), and all the non-CpG dinucleotide G:C to A:T mutations of p53 were ... methylation of the promoter region of their MGMT gene. MGMT can prevent G to A mutations by removing alkyl ...

    Abstract The DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) removes alkylating adducts from the O(6) position of guanine and protects cells from cytotoxic and mutagenic effects. Expression of MGMT is decreased in some cancers, which may be the result of methylation of CpG islands of both the promoter and coding regions of the gene. We studied the methylation status of the MGMT promoter in a very large collection of brain tumors (85) using methylation-specific polymerase chain reaction (PCR). Aberrant methylation occurred in 48% of 85 human brain tumor samples. Quantitative real-time PCR showed that expression of MGMT mRNA levels was significantly decreased (P < 0.001) in those brain tumors that had methylation of the promoter region of their MGMT gene. MGMT can prevent G to A mutations by removing alkyl groups from the O(6) position of guanine. We found a significantly increased frequency of G:C to A:T mutations of the p53 gene in brain tumors having a methylated MGMT promoter compared with those having an unmethylated MGMT promoter (P < 0.05), and all the non-CpG dinucleotide G:C to A:T mutations of p53 were in samples with a methylated MGMT promoter.
    MeSH term(s) Base Sequence ; Brain Neoplasms/enzymology ; Brain Neoplasms/genetics ; DNA Methylation ; DNA Primers ; DNA Repair ; Humans ; O(6)-Methylguanine-DNA Methyltransferase/genetics ; Point Mutation ; Polymerase Chain Reaction ; Promoter Regions, Genetic ; Tumor Cells, Cultured
    Chemical Substances DNA Primers ; O(6)-Methylguanine-DNA Methyltransferase (EC 2.1.1.63)
    Language English
    Publishing date 2003-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 1004029-8
    ISSN 1098-2744 ; 0899-1987
    ISSN (online) 1098-2744
    ISSN 0899-1987
    DOI 10.1002/mc.10094
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Book: Einführung in die moderne kognitive Verhaltenstherapie

    Hofmann, Stefan G. / Hildebrandt, Angelika / Schnell, Thomas

    psychotherapeutische Lösungsansätze

    2013  

    Title translation An introduction to modern CBT
    Author's details Stefan G. Hofmann. Aus dem Amerikan. übers. von Angelika Hildebrandt
    Keywords Cognitive Therpy / methods ; Mental Disorders / therapy ; Kognitive Verhaltenstherapie
    Subject Kognitive Verhaltensmodifikation ; Kognitiv-behaviorale Therapie ; KVT
    Language German
    Size XIX, 207 S. : graph. Darst.
    Edition Dt. Ausg.
    Publisher Springer VS
    Publishing place Berlin u.a.
    Publishing country Germany
    Document type Book
    Note Aus dem Engl. übers.
    HBZ-ID HT017620445
    ISBN 978-3-642-35199-0 ; 3-642-35199-9 ; 9783642352003 ; 3642352006
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Article: Ein neuer Salmonellayp: S. hamburg (1, 9, 12:g, t:-)

    ROHDE, R / HOFMANN, S

    Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. 1. Abt. Medizinisch-hygienische Bakteriologie, Virusforschung und Parasitologie. Originale

    1957  Volume 168, Issue 5-6, Page(s) 483–485

    Title translation A new Salmonella type: S. hamburg (1, 9, 12:g, t:-).
    MeSH term(s) Humans ; Salmonella
    Language German
    Publishing date 1957-05
    Publishing country Germany
    Document type Journal Article
    ISSN 0372-8110
    ISSN 0372-8110
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Rekonstruktion eines metadiaphysären Knochendefekts nach offener, mehrfragmentärer Fraktur des proximalen Femurs in modifizierter Masquelet-Technik.

    Fischer, C / Mendel, T / Hückstädt, M / Hofmann, G O / Klauke, F

    Unfallchirurgie (Heidelberg, Germany)

    2023  Volume 126, Issue 10, Page(s) 812–816

    Abstract: The reconstruction of segmental bone defects after surgical treatment of infected delayed unions as well as nonunions, places the highest demands on the surgical technical implementation. After treating the fracture-related infection, guaranteeing ... ...

    Title translation Reconstruction of a metadiaphyseal bone defect after open comminuted fracture of the proximal femur using a modified Masquelet technique.
    Abstract The reconstruction of segmental bone defects after surgical treatment of infected delayed unions as well as nonunions, places the highest demands on the surgical technical implementation. After treating the fracture-related infection, guaranteeing biomechanical stability is crucial for the success of the treatment. The presented case describes the successful treatment of an infected delayed union after an open metadiaphyseal comminuted fracture of the proximal femur using a modified Masquelet technique. A solid allogeneic bone graft in combination with autologous cancellous bone were inserted into a 7 cm subtrochanteric defect zone and stabilized with a combined plate and nail osteosynthesis.
    MeSH term(s) Humans ; Fractures, Comminuted/surgery ; Fracture Healing ; Fractures, Open/surgery ; Femur ; Lower Extremity
    Language German
    Publishing date 2023-01-04
    Publishing country Germany
    Document type English Abstract ; Journal Article
    ISSN 2731-703X
    ISSN (online) 2731-703X
    DOI 10.1007/s00113-022-01278-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Geschlossene Reposition und minimal-invasive Fixation einer sakralen Ausbruchfraktur : Minimale Invasivität bei maximaler Stabilität.

    Klauke, F / Hofmann, G O / Mendel, T

    Die Unfallchirurgie

    2021  Volume 125, Issue 6, Page(s) 492–496

    Abstract: Surgical stabilization of high-energy sacral avulsion fractures with spinopelvic dissociation places high demands on the surgeon. The goal is to achieve maximum stability while minimizing invasiveness. The present case of a dislocated U‑type fracture in ... ...

    Title translation Closed reduction and minimally invasive fixation of a sacral avulsion fracture : Minimal invasiveness with maximum stability.
    Abstract Surgical stabilization of high-energy sacral avulsion fractures with spinopelvic dissociation places high demands on the surgeon. The goal is to achieve maximum stability while minimizing invasiveness. The present case of a dislocated U‑type fracture in a 25-year-old motocross rider exemplifies how a reduction with the targeted application of closed reduction techniques through hyperextension of the hip joints and lordosis in the lumbosacral hinge and through a standardized procedure in intraoperative fluoroscopic imaging, a minimally invasive stabilization by means of transsacral screw fixation and spinopelvic fixation of lumbar vertebra 5 to the ilium in the sense of a bilateral triangular stabilization is possible without compromising the achieved stability of the osteosynthesis. The limitations of the described approach are also pointed out.
    MeSH term(s) Adult ; Bone Screws ; Fractures, Avulsion ; Fractures, Bone/surgery ; Humans ; Muscular Diseases ; Neck Injuries ; Sacrum/diagnostic imaging ; Spinal Fractures/diagnostic imaging
    Language German
    Publishing date 2021-06-23
    Publishing country Germany
    Document type Case Reports ; Journal Article
    ISSN 2731-703X
    ISSN (online) 2731-703X
    DOI 10.1007/s00113-021-01035-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Berufskrankheit „Läsion der Rotatorenmanschette der Schulter”. Narratives Review zu den möglichen außerberuflichen (konkurrierenden) Risikofaktoren. Occupational disease „rotator cuff disease of the shoulder”. Narrative review of the possible non-occupational (competing) risk factors.

    Spahn, G. / Diener, G. L. / Klemm, T. / Hofmann, G. O. / Grifka, J. / Meyer-Clement, M.

    <> medizinische Sachverständige

    2023  Volume 119, Issue 5, Page(s) 195

    Language German
    Document type Article
    ZDB-ID 124110-2
    ISSN 0025-8490
    Database Current Contents Medicine

    More links

    Kategorien

  7. Article ; Online: Identification of responders to immune checkpoint therapy: which biomarkers have the highest value?

    Liebl, M C / Hofmann, T G

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2019  Volume 33 Suppl 8, Page(s) 52–56

    Abstract: Evasion of immune recognition by the innate and acquired immune system is a major principle of tumour cells and belongs to the hallmarks of cancer. Immune checkpoint inhibitor-based cancer therapies targeting the co-inhibitory receptors CTLA-4 or PD-1 ... ...

    Abstract Evasion of immune recognition by the innate and acquired immune system is a major principle of tumour cells and belongs to the hallmarks of cancer. Immune checkpoint inhibitor-based cancer therapies targeting the co-inhibitory receptors CTLA-4 or PD-1 have received enormous scientific and clinical attention during the last few years, because of promising clinical results observed in the treatment of different cancer entities including melanoma and cutaneous squamous cell carcinoma. However, the enthusiasm about the effects of the immune checkpoint inhibitors is muted as only a subfraction of patients shows a stable clinical response. To predefine the patient cohorts that may benefit from immune checkpoint therapy, rigorous biomarker analyses, which predict the response to these novel therapies, need to be performed. In addition, combination of immune checkpoint therapy with classical DNA-damaging chemotherapy or radiotherapy, which positively affects tumour neo-antigen presentation, appears to be a promising approach in optimizing patients' response. In this review, we briefly summarize important biomarkers for patient stratification and discuss the current limitations of these biomarkers in defining responders vs. non-responders to immune checkpoint therapy.
    MeSH term(s) Biomarkers, Tumor ; Humans ; Immunotherapy/methods ; Neoplasms/therapy ; Treatment Outcome
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2019-12-13
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/jdv.15992
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.

    Boess, F G / Scelsi, M A / Grimmer, T / Perry, R J / Tonietto, M / Klein, G / Hofmann, C / Salami, M / Wojtowicz, J / Lansdall, C J / Lane, C / Kerchner, G A / Smith, J / Doody, R S

    The journal of prevention of Alzheimer's disease

    2024  Volume 11, Issue 3, Page(s) 537–548

    Abstract: Background: Monoclonal antibodies that target amyloid-beta and remove amyloid plaques can slow cognitive and functional decline in early Alzheimer's disease. Gantenerumab is a subcutaneously administered fully-human anti-amyloid-beta monoclonal antibody ...

    Abstract Background: Monoclonal antibodies that target amyloid-beta and remove amyloid plaques can slow cognitive and functional decline in early Alzheimer's disease. Gantenerumab is a subcutaneously administered fully-human anti-amyloid-beta monoclonal antibody with highest affinity for aggregated amyloid-beta. Since the phase 3 GRADUATE trials did not meet the primary endpoint (change from baseline to Week 116 in Clinical Dementia Rating scale - Sum of Boxes), development of gantenerumab in sporadic Alzheimer's disease was stopped and all ongoing trials were terminated early due to sponsor decision. Subcutaneous administration at the clinic or at home by care partner would be an important option for other therapies in this class in order to increase flexibility and reduce overall burden. The insights obtained from the experience with gantenerumab home administration by care partner in the phase 2 GRADUATION trial will serve to guide the ongoing efforts with other anti-amyloid-beta antibodies.
    Objectives: To evaluate the pharmacodynamic effects on brain amyloid load of once weekly subcutaneous administration of gantenerumab and the safety and feasibility of home administration by care partners.
    Design: Phase 2, open-label, single arm study.
    Setting: Multicenter trial conducted in 33 sites in 8 countries from November 2020 to March 2023.
    Participants: Participants aged 50 to 90 with early symptomatic Alzheimer's disease (mild cognitive impairment/mild dementia due to Alzheimer's disease), and evidence of amyloid positron emission tomography positivity.
    Intervention: Participants could receive up to 255 mg gantenerumab once-weekly, administered subcutaneously at site or at home by healthcare professionals or non-healthcare-professional care partners.
    Measurements: The primary endpoint was the change from baseline to Week 52 and to Week 104 in brain amyloid load as measured by PET centiloid levels. The secondary endpoints were responses to the home administration questionnaire, plasma concentrations and safety.
    Results: The overall number of participants enrolled was 192, with a mean (standard deviation) amyloid PET load at baseline of 101.80 (29.80) centiloids. At the time of early study termination by sponsor, 149 participants had valid Week 52 amyloid PET data (primary endpoint), and 12 participants had an early termination PET within the pre-defined time range of Week 104. The mean change in amyloid PET from baseline to Week 52 and Week 104 was -26.19 centiloids (range: -75.6-15.8; n=149) and -35.48 centiloids (range: -63.2--7.0; n=12), respectively. Responses to the home administration questionnaire at Week 52 (n=148) indicated that the majority of care partners (88-97%) considered administration of study drug at home easy (30.4%) or very easy (57.4%), and convenient (25.7%) or very convenient (70.9%). Care partners felt confident (31.1%) or very confident (62.2%) and satisfied (29.7%) or very satisfied (64.9%) with giving the injection at home. Responses by care partners at Week 36 (n=72), Week 76 (n=126) and Week 104 (n=29) and participant (patient) assessment of convenience and satisfaction at these time points were similar. There were no new safety findings associated with gantenerumab administered subcutaneously once weekly at 255 mg or safety issues associated with at-home injections by non-healthcare professional care partners.
    Conclusions: Once-weekly subcutaneous home administration of the anti-amyloid-beta antibody gantenerumab by non-healthcare-professional care partners to participants with early Alzheimer's disease was feasible, safe, well tolerated, and considered as a convenient option by both the care partners and participants with Alzheimer's disease. Although gantenerumab's development has been stopped due to lack of efficacy, this approach has the potential to reduce the frequency of hospital/outpatient clinic visits required for treatment with other anti-amyloid-β antibodies and can increase flexibility of drug administration for people living with Alzheimer's disease and their families.
    MeSH term(s) Humans ; Alzheimer Disease/drug therapy ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/therapeutic use ; Aged ; Female ; Feasibility Studies ; Male ; Caregivers ; Positron-Emission Tomography ; Amyloid beta-Peptides/metabolism ; Injections, Subcutaneous ; Brain/drug effects ; Brain/metabolism ; Brain/diagnostic imaging ; Middle Aged ; Aged, 80 and over
    Chemical Substances gantenerumab (4DF060P933) ; Antibodies, Monoclonal, Humanized ; Amyloid beta-Peptides
    Language English
    Publishing date 2024-05-05
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Clinical Trial, Phase II ; Randomized Controlled Trial ; Multicenter Study
    ZDB-ID 2782183-3
    ISSN 2426-0266 ; 2274-5807
    ISSN (online) 2426-0266
    ISSN 2274-5807
    DOI 10.14283/jpad.2024.60
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Desmoid Fibromatosis Fused With a Lipoma in the Upper Arm.

    Traub, Frank / De Jager, Tobias / Hofmann, Ulf K / Farah, George / Sachsenmaier, Saskia M

    Cureus

    2024  Volume 16, Issue 3, Page(s) e55430

    Abstract: Lipoma, the most common mesenchymal tumor, often appears as a slow-growing mass in the musculoskeletal system (MSK). While generally non-invasive, their location can cause symptoms. Desmoid fibromatosis (DF), a rare and locally aggressive neoplasm, poses ...

    Abstract Lipoma, the most common mesenchymal tumor, often appears as a slow-growing mass in the musculoskeletal system (MSK). While generally non-invasive, their location can cause symptoms. Desmoid fibromatosis (DF), a rare and locally aggressive neoplasm, poses challenges in MSK system diagnosis and management due to its infiltrative nature. Despite lacking metastatic potential, DF has a high recurrence rate, classifying it as "intermediate, locally aggressive" in the WHO classification. Collaborative efforts among orthopedic surgeons, radiologists, and pathologists are crucial for accurate diagnosis and treatment planning for all tumors of the MSK system. This case report presents the first documented example of a DF within a lipoma, highlighting the challenges of diagnosing and treating musculoskeletal tumors.
    Language English
    Publishing date 2024-03-03
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.55430
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Morbus Castleman-assoziierter paraneoplastischer Pemphigus bei einer 16-jährigen Patientin.

    Bender, Sebastian T / Balakirski, Galina / Kteiche, Walid / Schmidt, Enno / Hofmann, Silke C

    Dermatologie (Heidelberg, Germany)

    2024  

    Abstract: Paraneoplastic pemphigus is a rare, life-threatening autoimmune disease that is clinically characterized by mostly extensive and refractory mucosal erosions and polymorphous skin lesions. We report here on a 16-year-old girl with isolated oral erosions, ... ...

    Title translation Paraneoplastic pemphigus with underlying Castleman's disease in a 16-year-old girl.
    Abstract Paraneoplastic pemphigus is a rare, life-threatening autoimmune disease that is clinically characterized by mostly extensive and refractory mucosal erosions and polymorphous skin lesions. We report here on a 16-year-old girl with isolated oral erosions, in whom mucosal pemphigoid was initially suspected and after treatment with prednisolone and dapsone marked improvement was achieved. However, a few months later the patient developed massive respiratory insufficiency as a result of bronchiolitis obliterans, so that a lung transplant was planned. As part of the preparatory diagnostic workup, unicentric, abdominally localized Castleman's disease was diagnosed, which ultimately led to the diagnosis of paraneoplastic pemphigus as evidenced by envoplakin autoantibodies. Tumor resection and subsequent lung transplantation achieved good results with sustained mucocutaneous remission.
    Language German
    Publishing date 2024-04-24
    Publishing country Germany
    Document type English Abstract ; Journal Article
    ISSN 2731-7013
    ISSN (online) 2731-7013
    DOI 10.1007/s00105-024-05328-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top